傲農生物(603363.SH)簽訂投資框架協議書 擬在詔安縣開展五項投資
格隆匯9月22日丨傲農生物(603363.SH)公佈,為加快推進公司主業發展,公司於近日與詔安縣人民政府簽署了《投資框架協議書》,雙方就在詔安縣投資建設現代農業開發項目達成合作意向。公司擬在詔安縣開展投資,項目總投資預計12億元人民幣,主要包含五項投資內容:一是新建一個年產30萬噸豬配合飼料加工廠;二是新建2個1萬頭母豬場和2至3個生態高效生豬養殖小區,合計年出欄50萬頭商品豬;三是新建一條年屠宰100萬頭商品豬、肉食品深加工生產線;四是新建一個年產4萬噸以上新型有機肥廠;五是現代農業科技示範園項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.